Shanghai Sixth People's Hospital
Shanghai, China
NCT Number: NCT07160998
This randomized, open-label, multicenter trial evaluates the efficacy and safety of the AI-based lifestyle guidance system (X-Life) compared to standard care in adults with type 2 diabetes. X-Life integrates glucose level, wearable devices, and AI-driven decision models to provide personalized lifestyle recommendations. The primary endpoint is the percentage of time in glucose target range (TIR).
Looking for future studies?
Notify Me40 year–70 year
All sexes
Interventional
Not applicable
Shanghai, China
Type 2 diabetes imposes a global health burden. Traditional care has limitations in accessibility, personalization, and long-term adherence. AI-driven digital therapeutics may overcome these barriers. X-Life is an innovative AI system providing individualized lifestyle guidance using glucose level and wearable data. User studies demonstrated usability and acceptability. This multicenter randomized controlled trial will rigorously test whether X-Life improves glycemic control compared with standard care, while also evaluating metabolic outcomes, patient-reported measures, and safety. The investigators designed this trial with the assistance of a digital twin-based clinical research system (termed X Town).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Personalized real-time lifestyle recommendations are delivered via via smartphone, tablet, etc., integrating glucose level and wearable data.
Participants receive standard diabetes management including medications and lifestyle recommendations based on guidelines.
Time frame: Run-in period (Day -7 to Day 0) and intervention period (Day 1 to Day 28)
Percentage of glucose readings within 3.9-10 mmol/L measured by CGM
Time frame: Run-in period (Day -7 to Day 0) and intervention period (Day 1 to Day 28)
mean glucose, SD, CV, TAR (>10 mmol/L), TBR (<3.9 and <3.0 mmol/L), daytime/nighttime TIR, MAGE, MODD, AUC, etc.
Time frame: Baseline and 28 days
Using DDS, DSCS, Self-Efficacy, WHO-5 scales, etc.
Time frame: At 28 days
Evaluation in X Life group only. User experience will be assessed using a validated questionnaire covering usability, usefulness, satisfaction, and acceptability. Each item is rated on a 5-point Likert scale. Higher scores indicate better user experience.
Time frame: Day 1-28 (intervention period)
Number of participants with CGM-recorded or symptomatic hypoglycemia (<3.9 mmol/L). Number of participants experiencing any AE/SAE.
Time frame: Baseline and 28 days
Plasma glucose at 0, 60, and 120 minutes during OGTT.
Time frame: Baseline and 28 days
Serum insulin at 0, 60, and 120 minutes during OGTT.
Time frame: Baseline and 28 days
Serum C-peptide at 0, 60, and 120 minutes during OGTT.
Time frame: Baseline and 28 days
Body weight (kg) measured using digital scale.
Time frame: Baseline and 28 days
Calculated as weight (kg) / height (m²).
Time frame: Baseline and 28 days
Measured at the midpoint between the lowest rib and iliac crest.
Time frame: Baseline and 28 days
Hip circumference measured at the widest part of the buttocks using a non-stretchable tape.
Time frame: Baseline and 28 days
Mid-thigh circumference measured at the midpoint between the inguinal crease and the proximal border of the patella.
Time frame: Baseline and 28 days
Average of two seated measurements.
Time frame: Baseline and 28 days
Average of two seated measurements.
Time frame: Baseline and 28 days
Measured by automated device after 5 minutes rest.
Time frame: Baseline and 28 days
Total cholesterol, LDL-C, HDL-C, and triglycerides.
Time frame: Baseline and 28 days
ALT, AST, GGT, etc.
Time frame: Baseline and 28 days
Serum creatinine, eGFR, etc.
Time frame: Baseline and 28 days
C-reactive protein
Time frame: Run-in end (Day 0), Intervention end (Day 28), Follow-up end (Day 35)
Psychological and behavioral outcomes will be assessed using multiple validated questionnaires. Each scale will be reported and analyzed separately: Diabetes Distress Scale (DDS): 17 items, scored 1-6; higher scores indicate greater distress; General Self-Efficacy Scale (GSES): 10 items, scored 1-4, total 10-40; higher scores indicate stronger self-efficacy; WHO-5 Well-Being Index: 5 items, raw score 0-25 transformed to 0-100; higher scores indicate better well-being; Summary of Diabetes Self-Care Activities (SDSCA): Items scored 0-7 days per week; higher scores indicate better diabetes self-management behaviors.
Li Huating
Other
Acronym: X Life
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial DetailsNCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial Details